 | • レポートコード：MRC2-11QY04472 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は治療用組換え抗体・タンパク質のグローバル市場について調査・分析したレポートです。種類別（血漿たんぱく質、融合たんぱく質、モノクローナル抗体、ホルモン、酵素、凝固因子、その他）市場規模、用途別（腫瘍学、血液学、免疫学、内分泌学、感染症、心血管疾患、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別治療用組換え抗体・タンパク質の競争状況、市場シェア ・世界の治療用組換え抗体・タンパク質市場：種類別市場規模 2015年-2020年（血漿たんぱく質、融合たんぱく質、モノクローナル抗体、ホルモン、酵素、凝固因子、その他） ・世界の治療用組換え抗体・タンパク質市場：種類別市場規模予測 2021年-2026年（血漿たんぱく質、融合たんぱく質、モノクローナル抗体、ホルモン、酵素、凝固因子、その他） ・世界の治療用組換え抗体・タンパク質市場：用途別市場規模 2015年-2020年（腫瘍学、血液学、免疫学、内分泌学、感染症、心血管疾患、その他） ・世界の治療用組換え抗体・タンパク質市場：用途別市場規模予測 2021年-2026年（腫瘍学、血液学、免疫学、内分泌学、感染症、心血管疾患、その他） ・北米の治療用組換え抗体・タンパク質市場分析：米国、カナダ ・ヨーロッパの治療用組換え抗体・タンパク質市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの治療用組換え抗体・タンパク質市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の治療用組換え抗体・タンパク質市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの治療用組換え抗体・タンパク質市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Abbott、Amgen、Biogen、Eli Lilly、Roche、Johnson and Johnson、Merck、Novo Nordisk、Pfizer、Sanofi ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
Market Analysis and Insights: Global Recombinant Therapeutic Antibodies and Proteins Market
The global Recombinant Therapeutic Antibodies and Proteins market size is projected to reach US$ 96180 million by 2026, from US$ 89490 million in 2020, at a CAGR of 6.9%% during 2021-2026.
Global Recombinant Therapeutic Antibodies and Proteins Scope and Market Size
Recombinant Therapeutic Antibodies and Proteins market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Therapeutic Antibodies and Proteins market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Market segment by Type, the product can be split into
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Market segment by Application, split into
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Recombinant Therapeutic Antibodies and Proteins Revenue
1.4 Market by Type
1.4.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Plasma Protein
1.4.3 Fusion Proteins
1.4.4 Monoclonal Antibodies
1.4.5 Hormones
1.4.6 Enzyme
1.4.7 Coagulation Factors
1.4.8 Others
1.5 Market by Application
1.5.1 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Application: 2020 VS 2026
1.5.2 Oncology
1.5.3 Hematology
1.5.4 Immunology
1.5.5 Endocrinology
1.5.6 Infectious Disease
1.5.7 Cardiovascular Disease
1.5.8 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Perspective (2015-2026)
2.2 Global Recombinant Therapeutic Antibodies and Proteins Growth Trends by Regions
2.2.1 Recombinant Therapeutic Antibodies and Proteins Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Recombinant Therapeutic Antibodies and Proteins Historic Market Share by Regions (2015-2020)
2.2.3 Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Recombinant Therapeutic Antibodies and Proteins Market Growth Strategy
2.3.6 Primary Interviews with Key Recombinant Therapeutic Antibodies and Proteins Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Market Size
3.1.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue (2015-2020)
3.1.2 Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Players (2015-2020)
3.1.3 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio
3.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Recombinant Therapeutic Antibodies and Proteins Revenue in 2019
3.3 Recombinant Therapeutic Antibodies and Proteins Key Players Head office and Area Served
3.4 Key Players Recombinant Therapeutic Antibodies and Proteins Product Solution and Service
3.5 Date of Enter into Recombinant Therapeutic Antibodies and Proteins Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Type (2015-2020)
4.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
5.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
6.2 Recombinant Therapeutic Antibodies and Proteins Key Players in North America (2019-2020)
6.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
6.4 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
7 Europe
7.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
7.2 Recombinant Therapeutic Antibodies and Proteins Key Players in Europe (2019-2020)
7.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
7.4 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
8 China
8.1 China Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
8.2 Recombinant Therapeutic Antibodies and Proteins Key Players in China (2019-2020)
8.3 China Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
8.4 China Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
9 Japan
9.1 Japan Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
9.2 Recombinant Therapeutic Antibodies and Proteins Key Players in Japan (2019-2020)
9.3 Japan Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
9.4 Japan Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
10.2 Recombinant Therapeutic Antibodies and Proteins Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
10.4 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
11 India
11.1 India Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
11.2 Recombinant Therapeutic Antibodies and Proteins Key Players in India (2019-2020)
11.3 India Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
11.4 India Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
12.2 Recombinant Therapeutic Antibodies and Proteins Key Players in Central & South America (2019-2020)
12.3 Central & South America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
12.4 Central & South America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Abbott
13.1.1 Abbott Company Details
13.1.2 Abbott Business Overview
13.1.3 Abbott Recombinant Therapeutic Antibodies and Proteins Introduction
13.1.4 Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020))
13.1.5 Abbott Recent Development
13.2 Amgen
13.2.1 Amgen Company Details
13.2.2 Amgen Business Overview
13.2.3 Amgen Recombinant Therapeutic Antibodies and Proteins Introduction
13.2.4 Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
13.2.5 Amgen Recent Development
13.3 Biogen
13.3.1 Biogen Company Details
13.3.2 Biogen Business Overview
13.3.3 Biogen Recombinant Therapeutic Antibodies and Proteins Introduction
13.3.4 Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
13.3.5 Biogen Recent Development
13.4 Eli Lilly
13.4.1 Eli Lilly Company Details
13.4.2 Eli Lilly Business Overview
13.4.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Introduction
13.4.4 Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
13.4.5 Eli Lilly Recent Development
13.5 Roche
13.5.1 Roche Company Details
13.5.2 Roche Business Overview
13.5.3 Roche Recombinant Therapeutic Antibodies and Proteins Introduction
13.5.4 Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
13.5.5 Roche Recent Development
13.6 Johnson and Johnson
13.6.1 Johnson and Johnson Company Details
13.6.2 Johnson and Johnson Business Overview
13.6.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Introduction
13.6.4 Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
13.6.5 Johnson and Johnson Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview
13.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Introduction
13.7.4 Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Novo Nordisk
13.8.1 Novo Nordisk Company Details
13.8.2 Novo Nordisk Business Overview
13.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Introduction
13.8.4 Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
13.8.5 Novo Nordisk Recent Development
13.9 Pfizer
13.9.1 Pfizer Company Details
13.9.2 Pfizer Business Overview
13.9.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Introduction
13.9.4 Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
13.9.5 Pfizer Recent Development
13.10 Sanofi
13.10.1 Sanofi Company Details
13.10.2 Sanofi Business Overview
13.10.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Introduction
13.10.4 Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
13.10.5 Sanofi Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Recombinant Therapeutic Antibodies and Proteins Key Market Segments
Table 2. Key Players Covered: Ranking by Recombinant Therapeutic Antibodies and Proteins Revenue
Table 3. Ranking of Global Top Recombinant Therapeutic Antibodies and Proteins Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Plasma Protein
Table 6. Key Players of Fusion Proteins
Table 7. Key Players of Monoclonal Antibodies
Table 8. Key Players of Hormones
Table 9. Key Players of Enzyme
Table 10. Key Players of Coagulation Factors
Table 11. Key Players of Others
Table 12. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Regions (2015-2020)
Table 16. Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Recombinant Therapeutic Antibodies and Proteins Market Growth Strategy
Table 22. Main Points Interviewed from Key Recombinant Therapeutic Antibodies and Proteins Players
Table 23. Global Recombinant Therapeutic Antibodies and Proteins Revenue by Players (2015-2020) (Million US$)
Table 24. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Players (2015-2020)
Table 25. Global Top Recombinant Therapeutic Antibodies and Proteins Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Therapeutic Antibodies and Proteins as of 2019)
Table 26. Global Recombinant Therapeutic Antibodies and Proteins by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Recombinant Therapeutic Antibodies and Proteins Product Solution and Service
Table 29. Date of Enter into Recombinant Therapeutic Antibodies and Proteins Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020) (Million US$)
Table 32. Global Recombinant Therapeutic Antibodies and Proteins Market Size Share by Type (2015-2020)
Table 33. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2021-2026)
Table 34. Global Recombinant Therapeutic Antibodies and Proteins Market Size Share by Application (2015-2020)
Table 35. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020) (Million US$)
Table 36. Global Recombinant Therapeutic Antibodies and Proteins Market Size Share by Application (2021-2026)
Table 37. North America Key Players Recombinant Therapeutic Antibodies and Proteins Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Recombinant Therapeutic Antibodies and Proteins Market Share (2019-2020)
Table 39. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020) (Million US$)
Table 40. North America Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2015-2020)
Table 41. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020) (Million US$)
Table 42. North America Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2015-2020)
Table 43. Europe Key Players Recombinant Therapeutic Antibodies and Proteins Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Recombinant Therapeutic Antibodies and Proteins Market Share (2019-2020)
Table 45. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2015-2020)
Table 47. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2015-2020)
Table 49. China Key Players Recombinant Therapeutic Antibodies and Proteins Revenue (2019-2020) (Million US$)
Table 50. China Key Players Recombinant Therapeutic Antibodies and Proteins Market Share (2019-2020)
Table 51. China Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020) (Million US$)
Table 52. China Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2015-2020)
Table 53. China Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020) (Million US$)
Table 54. China Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2015-2020)
Table 55. Japan Key Players Recombinant Therapeutic Antibodies and Proteins Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Recombinant Therapeutic Antibodies and Proteins Market Share (2019-2020)
Table 57. Japan Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2015-2020)
Table 59. Japan Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Recombinant Therapeutic Antibodies and Proteins Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Recombinant Therapeutic Antibodies and Proteins Market Share (2019-2020)
Table 63. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2015-2020)
Table 65. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2015-2020)
Table 67. India Key Players Recombinant Therapeutic Antibodies and Proteins Revenue (2019-2020) (Million US$)
Table 68. India Key Players Recombinant Therapeutic Antibodies and Proteins Market Share (2019-2020)
Table 69. India Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020) (Million US$)
Table 70. India Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2015-2020)
Table 71. India Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020) (Million US$)
Table 72. India Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Recombinant Therapeutic Antibodies and Proteins Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Recombinant Therapeutic Antibodies and Proteins Market Share (2019-2020)
Table 75. Central & South America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Recombinant Therapeutic Antibodies and Proteins Market Share by Type (2015-2020)
Table 77. Central & South America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Recombinant Therapeutic Antibodies and Proteins Market Share by Application (2015-2020)
Table 79. Abbott Company Details
Table 80. Abbott Business Overview
Table 81. Abbott Product
Table 82. Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 83. Abbott Recent Development
Table 84. Amgen Company Details
Table 85. Amgen Business Overview
Table 86. Amgen Product
Table 87. Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 88. Amgen Recent Development
Table 89. Biogen Company Details
Table 90. Biogen Business Overview
Table 91. Biogen Product
Table 92. Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 93. Biogen Recent Development
Table 94. Eli Lilly Company Details
Table 95. Eli Lilly Business Overview
Table 96. Eli Lilly Product
Table 97. Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 98. Eli Lilly Recent Development
Table 99. Roche Company Details
Table 100. Roche Business Overview
Table 101. Roche Product
Table 102. Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 103. Roche Recent Development
Table 104. Johnson and Johnson Company Details
Table 105. Johnson and Johnson Business Overview
Table 106. Johnson and Johnson Product
Table 107. Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 108. Johnson and Johnson Recent Development
Table 109. Merck Company Details
Table 110. Merck Business Overview
Table 111. Merck Product
Table 112. Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 113. Merck Recent Development
Table 114. Novo Nordisk Business Overview
Table 115. Novo Nordisk Product
Table 116. Novo Nordisk Company Details
Table 117. Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 118. Novo Nordisk Recent Development
Table 119. Pfizer Company Details
Table 120. Pfizer Business Overview
Table 121. Pfizer Product
Table 122. Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 123. Pfizer Recent Development
Table 124. Sanofi Company Details
Table 125. Sanofi Business Overview
Table 126. Sanofi Product
Table 127. Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020) (Million US$)
Table 128. Sanofi Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Type: 2020 VS 2026
Figure 2. Plasma Protein Features
Figure 3. Fusion Proteins Features
Figure 4. Monoclonal Antibodies Features
Figure 5. Hormones Features
Figure 6. Enzyme Features
Figure 7. Coagulation Factors Features
Figure 8. Others Features
Figure 9. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Application: 2020 VS 2026
Figure 10. Oncology Case Studies
Figure 11. Hematology Case Studies
Figure 12. Immunology Case Studies
Figure 13. Endocrinology Case Studies
Figure 14. Infectious Disease Case Studies
Figure 15. Cardiovascular Disease Case Studies
Figure 16. Others Case Studies
Figure 17. Recombinant Therapeutic Antibodies and Proteins Report Years Considered
Figure 18. Global Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth 2015-2026 (US$ Million)
Figure 19. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Regions: 2020 VS 2026
Figure 20. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Regions (2021-2026)
Figure 21. Porter's Five Forces Analysis
Figure 22. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Players in 2019
Figure 23. Global Top Recombinant Therapeutic Antibodies and Proteins Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Therapeutic Antibodies and Proteins as of 2019
Figure 24. The Top 10 and 5 Players Market Share by Recombinant Therapeutic Antibodies and Proteins Revenue in 2019
Figure 25. North America Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Europe Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. China Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Japan Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. India Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Central & South America Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2015-2020) (Million US$)
Figure 32. Bottom-up and Top-down Approaches for This Report
Figure 33. Data Triangulation
Figure 34. Key Executives Interviewed
組換えヒトタンパク質の世界市場（～2026年） Recombinant proteins are used throughout biological and biomedical science. Their production was once the domain of experts, but the development of simple, commercially available systems has made the technology more widespread. Market Analysis and Insights: Global Recombinant Human Proteins Market T…- バイオエンジニアリングタンパク質医薬品の世界市場（～2026年） Market Analysis and Insights: Global Bioengineered Proteins Drugs Market The global Bioengineered Proteins Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Bioengineered Proteins Drugs Scope and Market Size Bioeng…
- モノクローナル抗体(mAb)バイオシミラーの世界市場（～2026年） A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of q…
- 診断用特殊抗体の世界市場（～2026年） Market Analysis and Insights: Global Diagnostic Specialty Antibodies Market The global Diagnostic Specialty Antibodies market size is projected to reach US$ 20750 million by 2026, from US$ 20090 million in 2020, at a CAGR of 3.0%% during 2021-2026. Global Diagnostic Specialty Antibodies Scope and Ma…
- レクティス（炭水化物結合タンパク質）の世界市場（～2026年） Market Analysis and Insights: Global Lectis(Carbohydrate Binding Proteins) Market The global Lectis(Carbohydrate Binding Proteins) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Lectis(Carbohydrate Binding Proteins) S…